STAT3 has been shown to be upregulated and more active in cetuximab-resistant HNSCC cell lines, and its inhibition decreased cell growth in cell lines resistant to anti-EGFR therapy [130, 131]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.